SEAT DEVICE FOR VEHICLE
    1.
    发明申请
    SEAT DEVICE FOR VEHICLE 审中-公开
    车辆座椅装置

    公开(公告)号:US20090248257A1

    公开(公告)日:2009-10-01

    申请号:US12395644

    申请日:2009-02-28

    IPC分类号: G06F17/00 G08B23/00

    摘要: An egress-start determining device determines a start of egress of a passenger seated in a seat of a vehicle. A completion determining device determines completion of a driver's head moving out of a door opening of the vehicle after the start of egress of the passenger. A seat-sitting-face height adjusting device adjusts a height of a sitting face of the seat in such a manner that the height is adjusted to a first height during a time from the start of egress of the passenger to the completion of the driver's head moving out of the door opening of the vehicle, and the height is adjusted to a second height after the completion of the driver's head moving out of the door opening of the vehicle.

    摘要翻译: 出口开始确定装置确定坐在车辆座椅中的乘客的出发开始。 完成确定装置确定驾驶员的头部在乘客出口开始之后从车门开口移出的完成。 座椅坐面高度调节装置以从乘客出口开始到驾驶员头部完成的时间内将高度调整到第一高度的方式调节座椅的坐立面的高度 从车门的开口移出,并且在驾驶员头部从车门开口移出之后将高度调整到第二高度。

    Tetrahydrobenzazepine derivatives which inhibit lipoxygenase
    2.
    发明授权
    Tetrahydrobenzazepine derivatives which inhibit lipoxygenase 失效
    抑制脂氧合酶的四氢苯并吖庚因衍生物

    公开(公告)号:US5478822A

    公开(公告)日:1995-12-26

    申请号:US167959

    申请日:1993-12-17

    CPC分类号: C07D223/16

    摘要: Compounds of the formula ##STR1## wherein n is 1 to 5 and R is hydrogen, C.sub.1 to C.sub.4 alkyl, arylalkyl having from one to four carbon atoms in the alkyl moiety or arylalkyl substituted with one or more substituents selected independently from the group consisting of halogen, nitro, cyano, C.sub.1 to C.sub.6 alkyl, C.sub.1 to C.sub.6 alkoxy, C.sub.1 to C.sub.6 halosubstituted alkyl, C.sub.1 to C.sub.6 hydroxysubstituted alkyl, C.sub.2 to C.sub.7 alkoxycarbonyl and aminocarbonyl, and the pharmaceutically acceptable salts thereof, inhibit the enzyme lipoxygenase and are useful in treating allergy and inflammatory and cardiovascular conditions for which the action of lipoxygenase has been implicated. These compounds form the active ingredient in pharmaceutical compositions for treating such conditions.

    摘要翻译: PCT No.PCT / US92 / 04197 Sec。 371日期:1993年12月17日 102(e)1993年12月17日PCT PCT。1992年5月27日提交PCT。其中n为1至5,R为氢,C 1至C 4烷基,具有1至4个碳原子的芳基烷基的式 被一个或多个独立地选自卤素,硝基,氰基,C 1至C 6烷基,C 1至C 6烷氧基,C 1至C 6卤代烷基,C 1至C 6羟基取代的烷基,C 2至C 7烷氧羰基和 氨基羰基及其药学上可接受的盐抑制酶脂氧合酶,并且可用于治疗已经涉及脂氧合酶作用的过敏和炎性和心血管疾病。 这些化合物在用于治疗这些病症的药物组合物中形成活性成分。